Results 131 to 140 of about 92,863 (145)
Some of the next articles are maybe not open access.
Pharmacology of apolipoprotein A-l
Current Opinion in Lipidology, 1997The role of HDL and its main protein component the apolipoprotein A-I as being antiatherogenic is well established. Experimental data give support for the involvement of at least three different types of mechanism: (1) the reverse cholesterol transport, (2) anti-inflammatory mechanisms and (3) antithrombotic mechanisms.
openaire +2 more sources
Apolipoprotein E gene expression is reduced in apolipoprotein A-I transgenic mice
Molecular and Cellular Biochemistry, 2000The levels of plasma apolipoprotein (apo) E, an anti-atherogenic protein involved in mammalian cholesterol transport, were found to be 2-3 fold lower in mice over-expressing human apoA-I gene. ApoE is mainly associated with VLDL and HDL-size particles, but in mice the majority of the apoE is associated with the HDL particles.
openaire +2 more sources
Familial Apolipoprotein A-I Deficiency
2016Apolipoprotein (apo) A-I is the key structural protein of high-density lipoprotein (HDL) and is necessary for sustaining the circulating level of HDL. It has also been studied extensively for its role in mediating many of the antiatherosclerotic and antithrombotic properties of HDL.
openaire +1 more source
[Familial apolipoprotein A-I variants].
Nihon rinsho. Japanese journal of clinical medicine, 2000Apolipoprotein (apo) A-I is the major apolipoprotein of HDL and is a single polypeptide chain with 243 amino acid residues. Familial apo A-I deficiency is a rare metabolic disorder of which 13 cases have been characterized at the molecular level. However, in subjects with apo A-I deficiency, coronary artery disease is not always present.
openaire +1 more source
Synthesis and secretion of apolipoprotein A-I
Biochemical Society Transactions, 1993CALANDRA BUONAURA, Sebastiano +1 more
openaire +2 more sources
SERUM APOLIPOPROTEIN A-I LEVELS
American Journal of Epidemiology, 1982NANCY R. PHILLIPS +2 more
openaire +1 more source
[Lipid-poor apolipoprotein A-I, glycated apolipoprotein A-I].
Nihon rinsho. Japanese journal of clinical medicine, 2005Satoshi, Maeda +2 more
openaire +1 more source
Nihon rinsho. Japanese journal of clinical medicine, 2001
T, Nakamura, K, Tsujinaka, A, Kashiwagi
openaire +1 more source
T, Nakamura, K, Tsujinaka, A, Kashiwagi
openaire +1 more source
[Glycated apolipoprotein A-I].
Nihon rinsho. Japanese journal of clinical medicine, 1999K, Shishino, S, Saheki
openaire +1 more source